03.03.2014 Views

European Society of Mycobacteriology - Instituto Nacional de Saúde ...

European Society of Mycobacteriology - Instituto Nacional de Saúde ...

European Society of Mycobacteriology - Instituto Nacional de Saúde ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

PP-45<br />

Resistance, MDR and XDR <strong>of</strong> M. tuberculosis in Spain in the last years.<br />

P. Ruiz, M. Causse, F.J. Zerolo, J. Gutierrez, M. Casal<br />

Mycobacteria Reference Center. Department <strong>of</strong> Microbiology. Faculty <strong>of</strong> Medicine. HospitL “Reina S<strong>of</strong>ía” . Córdoba. Spain.<br />

Tuberculosis is among the leading causes <strong>of</strong> <strong>de</strong>ath worldwi<strong>de</strong>. The World Health Organization (WHO) estimates that<br />

32% <strong>of</strong> the world population is infected with Mycobacterium tuberculosis . The resistance to antituberculous drugs is a big<br />

problem to the control <strong>of</strong> the illness . The emergence <strong>of</strong> multidrug-resistant strains (MDR), extensively drug-resistant<br />

(XDR) and extreme drug-resistant (XXDR) strains, is a global problem that has ma<strong>de</strong> a consi<strong>de</strong>rable alarm. There is an<br />

increasing <strong>de</strong>mand to <strong>de</strong>terminate in vitro susceptibilities <strong>of</strong> clinical isolates to antimicrobial agents other than those<br />

consi<strong>de</strong>red primary drugs.<br />

The purpose <strong>of</strong> this study, was <strong>de</strong>terminate the resistance, MDR and XDR strains in our Reference Center in the four last years.<br />

Material and method<br />

We are studied 624 samples from patients suspects <strong>of</strong> tuberculosis. 355 strains <strong>of</strong> M. tuberculosis were isolates , in<br />

BACTEC MGIT 960 and Lowenstein -Jensen medium and i<strong>de</strong>ntified using Accuprobe and GENOTYPE MYCOBACTERIA.<br />

The susceptibility testing was ma<strong>de</strong> for primary drugs and: Amikacin (AK) 1.0 µg/ml; Kanamycin (K) 1 µg/ml; Capreomycin<br />

(CM) 2.5 µg/ml; Ethionamy<strong>de</strong> (ETH) 5.0 µg/ml; Ofloxacin (OF) 2.0 µg/ml; Cipr<strong>of</strong>loxacin (CI) 2 µg/ml ; Moxifloxacin (MX)<br />

2 µg/ml; Lev<strong>of</strong>loxacin (LE) 4µg/ml; Rifabutin (Rb) 0.5 µg/ml ;Rifapentine 5 µg/ml and Linezolid (Lz) 1.0 µg/ml. The Bactec<br />

MGIT technique with standart protocol was strictly followed as recommen<strong>de</strong>d,<br />

Results<br />

From 624 samples, in 355 were isolated M. tuberculosis and 55 (15,49 %) <strong>of</strong> theme were resistant to some <strong>of</strong> the antimicrobial<br />

agents studied. The resistance to streptomycin was 3´38 %, to rifampin 7,88%. ethambutol 1,12 %, isoniazid 11.26<br />

% and pyrazinami<strong>de</strong> 1,97%. A 7,6 % <strong>of</strong> strains were resistant to some <strong>of</strong> the second line drugs.The MDR was 5,6 % and<br />

the XDR 1,4 %. No XXDR were isolated.<br />

Conclusion<br />

The resistance to secondary drugs ma<strong>de</strong> necessary the in vitro studies. This method, BACTEC MGIT 960 is a reliable and<br />

rapid method to <strong>de</strong>terminate the secondary drugs.<br />

<strong>European</strong> <strong>Society</strong> <strong>of</strong> <strong>Mycobacteriology</strong> | 30 th Annual Congress | July 2009 | Porto - Portugal<br />

117

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!